Novavax Inc. (NASDAQ:NVAX) has received a consensus rating of “Buy” from the eleven analysts that are covering the stock. Six equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $5.98.

Several analysts have recently commented on NVAX shares. Piper Jaffray Cos. restated an “overweight” rating and issued a $14.00 target price on shares of Novavax in a research note on Friday, September 9th. FBR & Co restated an “outperform” rating and issued a $12.00 target price on shares of Novavax in a research note on Monday, October 10th. Vetr cut shares of Novavax from a “strong-buy” rating to a “buy” rating and set a $7.86 target price for the company. in a research note on Monday, August 15th. Wedbush restated an “outperform” rating and issued a $14.00 target price on shares of Novavax in a research note on Wednesday, July 27th. Finally, Zacks Investment Research upgraded shares of Novavax from a “sell” rating to a “hold” rating in a research note on Wednesday, September 21st.

Shares of Novavax (NASDAQ:NVAX) opened at 1.29 on Monday. Novavax has a 52 week low of $1.16 and a 52 week high of $9.23. The stock’s market cap is $349.84 million. The company’s 50-day moving average is $1.62 and its 200 day moving average is $5.12.

Novavax (NASDAQ:NVAX) last released its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.02. Novavax had a negative net margin of 1,908.41% and a negative return on equity of 189.14%. The company earned $3.20 million during the quarter, compared to analysts’ expectations of $4.02 million. During the same quarter last year, the business earned ($0.12) EPS. The business’s revenue was down 50.8% on a year-over-year basis. Analysts forecast that Novavax will post ($1.05) earnings per share for the current fiscal year.

In other Novavax news, Director Michael A. Mcmanus, Jr. bought 30,000 shares of the company’s stock in a transaction on Wednesday, September 21st. The stock was purchased at an average cost of $1.61 per share, for a total transaction of $48,300.00. Following the acquisition, the director now owns 247,590 shares of the company’s stock, valued at approximately $398,619.90. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP John Trizzino bought 46,000 shares of the company’s stock in a transaction on Thursday, September 22nd. The shares were acquired at an average price of $2.17 per share, with a total value of $99,820.00. Following the completion of the acquisition, the senior vice president now directly owns 85,564 shares in the company, valued at approximately $185,673.88. The disclosure for this purchase can be found here. Company insiders own 3.50% of the company’s stock.

A number of institutional investors have recently bought and sold shares of NVAX. Northpointe Capital LLC increased its stake in shares of Novavax by 47.2% in the second quarter. Northpointe Capital LLC now owns 2,124,035 shares of the biopharmaceutical company’s stock worth $15,442,000 after buying an additional 681,133 shares during the period. Candriam Luxembourg S.C.A. purchased a new stake in shares of Novavax during the second quarter worth approximately $1,692,000. Parametrica Management Ltd increased its stake in shares of Novavax by 43.1% in the second quarter. Parametrica Management Ltd now owns 29,760 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 8,960 shares during the period. Edge Wealth Management LLC increased its stake in shares of Novavax by 9.5% in the second quarter. Edge Wealth Management LLC now owns 82,370 shares of the biopharmaceutical company’s stock worth $599,000 after buying an additional 7,150 shares during the period. Finally, BNP Paribas Arbitrage SA increased its stake in shares of Novavax by 28.4% in the second quarter. BNP Paribas Arbitrage SA now owns 115,279 shares of the biopharmaceutical company’s stock worth $838,000 after buying an additional 25,488 shares during the period. Hedge funds and other institutional investors own 76.06% of the company’s stock.

Novavax Company Profile

Novavax, Inc (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases.

5 Day Chart for NASDAQ:NVAX

Receive News & Stock Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related stocks with our FREE daily email newsletter.